Header Logo

Connection

MARGARET SPITZ to Bleomycin

Back to Details
This is a "connection" page, showing publications MARGARET SPITZ has written about Bleomycin.
MARGARET SPITZ
Connection Strength
2.008
Bleomycin
  1. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res. 2006 Dec 01; 12(23):7194-201.
    View in: PubMed
    Score: 0.257
  2. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. Cancer. 1998 Sep 15; 83(6):1118-27.
    View in: PubMed
    Score: 0.145
  3. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst. 1998 Feb 04; 90(3):243-5.
    View in: PubMed
    Score: 0.139
  4. Mutagen sensitivity exhibits a dose-response relationship in case-control studies. Cancer Epidemiol Biomarkers Prev. 1996 Jul; 5(7):577-8.
    View in: PubMed
    Score: 0.125
  5. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev. 1995 Mar; 4(2):99-103.
    View in: PubMed
    Score: 0.114
  6. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases. Cancer Res. 1995 Feb 01; 55(3):557-61.
    View in: PubMed
    Score: 0.113
  7. Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug; 2(4):329-33.
    View in: PubMed
    Score: 0.101
  8. Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res. 1989 Aug 15; 49(16):4626-8.
    View in: PubMed
    Score: 0.077
  9. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila). 2008 Sep; 1(4):250-4.
    View in: PubMed
    Score: 0.072
  10. Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk. Int J Cancer. 2007 Jun 15; 120(12):2687-95.
    View in: PubMed
    Score: 0.067
  11. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.
    View in: PubMed
    Score: 0.057
  12. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8.
    View in: PubMed
    Score: 0.057
  13. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):113-23.
    View in: PubMed
    Score: 0.052
  14. Assessment of insulin-like growth factors and mutagen sensitivity as predictors of lung cancer risk. Methods Mol Med. 2003; 75:279-87.
    View in: PubMed
    Score: 0.049
  15. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res. 2002 May 15; 62(10):2813-8.
    View in: PubMed
    Score: 0.047
  16. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst. 2000 May 03; 92(9):737-43.
    View in: PubMed
    Score: 0.041
  17. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. Growth Horm IGF Res. 2000 Apr; 10 Suppl A:S26-7.
    View in: PubMed
    Score: 0.040
  18. Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res. 1999; 151:3-12.
    View in: PubMed
    Score: 0.037
  19. Genetic susceptibility to tobacco carcinogenesis. Cancer Invest. 1999; 17(8):645-59.
    View in: PubMed
    Score: 0.037
  20. Correspondence re: M. T. Goodman et al., effects of beta-carotene and alpha-tocopherol on bleomycin-induced chromosomal damage. Cancer Epidemiol. Biomark. Prev., 7: 113-117, 1998. Cancer Epidemiol Biomarkers Prev. 1998 Aug; 7(8):729.
    View in: PubMed
    Score: 0.036
  21. A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. Cancer Epidemiol Biomarkers Prev. 1997 Jul; 6(7):537-42.
    View in: PubMed
    Score: 0.033
  22. Survival of cells with bleomycin-induced chromosomal lesions in the cultured lymphocytes of lung cancer patients. Cancer Epidemiol Biomarkers Prev. 1996 Jul; 5(7):527-32.
    View in: PubMed
    Score: 0.031
  23. A statistical analysis of the reliability and classification error in application of the mutagen sensitivity assay. Cancer Epidemiol Biomarkers Prev. 1996 Mar; 5(3):191-7.
    View in: PubMed
    Score: 0.030
  24. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr. 1995; (18):29-33.
    View in: PubMed
    Score: 0.028
  25. Mutagen sensitivity as a marker of cancer risk. Cancer Detect Prev. 1994; 18(4):299-303.
    View in: PubMed
    Score: 0.026
  26. In vitro protective effects of chemopreventive agents against bleomycin-induced genotoxicity in lymphoblastoid cell lines and peripheral blood lymphocytes of head and neck cancer patients. Cancer Detect Prev. 1993; 17(6):575-83.
    View in: PubMed
    Score: 0.024
  27. Genetic and environmental interactions as risks for aerodigestive cancers. Adv Exp Med Biol. 1992; 320:31-4.
    View in: PubMed
    Score: 0.023
  28. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec; 1(1):83-9.
    View in: PubMed
    Score: 0.023
  29. Ethyl alcohol as a cocarcinogen with special reference to the aerodigestive tract: a cytogenetic study. Anticancer Res. 1991 May-Jun; 11(3):1097-101.
    View in: PubMed
    Score: 0.022
  30. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1935-40.
    View in: PubMed
    Score: 0.016
  31. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer. 2006 Jun 15; 106(12):2636-44.
    View in: PubMed
    Score: 0.016
  32. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst). 2003 Aug 12; 2(8):901-8.
    View in: PubMed
    Score: 0.013
  33. Comparative efficacy as antioxidants between ascorbic acid and epigallocatechin gallate on cells of two human lymphoblastoid lines. Cancer Genet Cytogenet. 2001 Jan 15; 124(2):169-71.
    View in: PubMed
    Score: 0.011
  34. Family history of cancer, mutagen sensitivity, and increased risk of head and neck cancer. Cancer Lett. 1999 Nov 01; 146(1):93-101.
    View in: PubMed
    Score: 0.010
  35. Three measures of mutagen sensitivity in a cancer-free population. Cancer Genet Cytogenet. 1999 Apr; 110(1):65-9.
    View in: PubMed
    Score: 0.009
  36. Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck. Clin Cancer Res. 1998 Jul; 4(7):1773-8.
    View in: PubMed
    Score: 0.009
  37. Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 1998 Jul; 7(7):567-70.
    View in: PubMed
    Score: 0.009
  38. Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients. Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr; 2(2):103-6.
    View in: PubMed
    Score: 0.006
  39. Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst. 1990 Nov 21; 82(22):1773-5.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.